Abstract Library

#2012 Expression and Clinical Significance of Vascular Endothelial Growth Factor D in Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: The expression of vascular endothelial growth factor D (VEGF-D) in tumor cells versus stroma cells in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and its clinical significance is still unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen L, Lin Y, Chen M, Chen J,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, vascular endothelial growth factor D, expression, clinical significance,

#2011 Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: The expression of vascular endothelial growth factor Receptor 3 (VEGFR3) and phospho-VEGFR3 (pVEGFR3) in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and their clinical significance are still unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen L, Lin Y, Chen M, Chen J,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, vascular endothelial growth factor Receptor 3, expression, clinical significance,

#2008 Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines

Introduction: Sunitinib and bevacizumab are intracellular and extracellular inhibitor of vascular endothelial growth factor(VEGF) pathway respectively, the influence of both of which on the proliferation of neuroendocrine neoplasm (NEN) cell lines in vitro was not known yet.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen L, Lin Y, Chen M, Chen J,

Keywords: neuroendocrine neoplasm, sunitinib, bevacizumab, VEGF pathway,

#1374 The Usefulness of Assessment the Serum Concentrations of Vascular Endothelial Growth Factor (VEGF) and Its Soluble Receptor Type 2 (VEGFR2) in Patients with Neuroendocrine Neoplasm (NEN)

Introduction: Angiogenesis plays an important role in tumour growth and disease progression. VEGF is a angiogenesis-stimulating factor. VEGFR2 has antiangiogenic properties.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Rosiek V, Kos-Kudła B, Zemczak A,

Keywords: neuroendocrine neoplasms, VEGF, VEGFR2,

#756 Evaluation of VEGF, VEGFR 1-2-3 and Endocan/ESM-1 Expression in Gastroenteropancreatic Neuroendocrine Tumors and Correlation with Ki-67 Labeling and Prognosis

Introduction: Angiogenesis is recognized to play a critical role in progressive tumor growth and spreading and its inhibition is a valuable approach to cancer treatment. Markers of angiogenesis include assessment of microvessel density on tissue sections (often evaluated with antibodies against pan-endothelial antigens, such as CD34) and expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR 1-2-3). Endocan, also called endothelial cell specific molecule-1 (ESM-1), has been shown to be expressed by endothelial tumor cells and especially by tip cells during angiogenesis. Endocan is highly up-regulated by pro-angiogenic molecules, such as VEGF. Recently, Endocan has been identified to be one of the molecules involved in the switch from dormant to fast-growing tumors. Among endocrine tumors, Endocan expression has been evaluated only in pituitary adenomas: a positive association between endothelial Endocan expression and recurrence risk, tumor size, tumoral invasion and average mitosis count has been demonstrated. In contrast, there was no association between endothelial Endocan expression and the Ki-67 labeling index

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Lugli F, Iacovazzo D, Fusco A, Lanza P, Rindi G,

Keywords: endocan, angiogenesis, vegf,